These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32603244)

  • 1. Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.
    Dalla Volta A; Mazziotti G; Maffezzoni F; Grisanti S; Palumbo C; Pedersini R; Maroldi R; Berruti A
    J Clin Oncol; 2020 Oct; 38(29):3363-3366. PubMed ID: 32603244
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment effect of breast cancer and prostate cancer on bone].
    Varsavsky M; Guadalix Iglesias S
    Med Clin (Barc); 2013 Feb; 140(4):164-8. PubMed ID: 22841464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The FRAX(®) tool in the prevention of fractures associated with androgenic deprivation therapy for prostate cancer].
    Azagra R; Zwart M; Martín-Sánchez JC; Aguyé A;
    Med Clin (Barc); 2014 Mar; 142(5):231-2. PubMed ID: 24018248
    [No Abstract]   [Full Text] [Related]  

  • 4. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.
    Briot K; Paccou J; Beuzeboc P; Bonneterre J; Bouvard B; Confavreux CB; Cormier C; Cortet B; Hannoun-Lévi JM; Hennequin C; Javier RM; Lespessailles E; Mayeur D; Mongiat Artus P; Vieillard MH; Debiais F
    Joint Bone Spine; 2019 Jan; 86(1):21-28. PubMed ID: 30287350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of fracture after androgen deprivation for prostate cancer.
    Walsh PC
    J Urol; 2005 Sep; 174(3):929-30. PubMed ID: 16093991
    [No Abstract]   [Full Text] [Related]  

  • 6. Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use.
    Cançado BL; Miranda LC; Madeira M; Farias ML
    Rev Col Bras Cir; 2015; 42(1):62-6. PubMed ID: 25992703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy.
    James H; Aleksic I; Bienz MN; Pieczonka C; Iannotta P; Albala D; Mariados N; Mouraviev V; Saad F
    Urology; 2014 Jul; 84(1):164-8. PubMed ID: 24976229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Osteoporosis in castration therapy--a neglected field].
    Bratt O; Akesson K
    Lakartidningen; 2011 Sep 28-Oct 4; 108(39):1902-5. PubMed ID: 22111227
    [No Abstract]   [Full Text] [Related]  

  • 10. Bone health during endocrine therapy for cancer.
    Rachner TD; Coleman R; Hadji P; Hofbauer LC
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):901-910. PubMed ID: 29572126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The skeletal impact of cancer therapies.
    Bedatsova L; Drake MT
    Br J Clin Pharmacol; 2019 Jun; 85(6):1161-1168. PubMed ID: 30723928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation in prostate cancer and the long-term risk of fracture.
    Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
    Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.
    Saylor PJ; Kaufman DS; Michaelson MD; Lee RJ; Smith MR
    J Urol; 2010 Jun; 183(6):2200-5. PubMed ID: 20399451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.
    Smith MR; Fallon MA; Goode MJ
    Urology; 2003 Jan; 61(1):127-31. PubMed ID: 12559282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effects of hormone deprivation therapy: weighing the evidence.
    Van Londen GJ; Lembersky BC
    Oncology (Williston Park); 2010 Aug; 24(9):846-7. PubMed ID: 20923042
    [No Abstract]   [Full Text] [Related]  

  • 17. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
    Takahashi S
    Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fracture risk in patients with prostate cancer on androgen deprivation therapy.
    López AM; Pena MA; Hernández R; Val F; Martín B; Riancho JA
    Osteoporos Int; 2005 Jun; 16(6):707-11. PubMed ID: 15714259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Osteoporosis fracture in a male patient secondary to hypogonadism due to androgen deprivation treatment for prostate cancer].
    Verdú Solans J; Roig Grau I; Almirall Banqué C
    Semergen; 2014; 40(4):e73-6. PubMed ID: 23768568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.